Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Akio Katayama"'
Autor:
Koji Nanmoku, Takayuki Yamamoto, Makoto Tsujita, Takahisa Hiramitsu, Norihiko Goto, Akio Katayama, Shunji Narumi, Yoshihiko Watarai, Takaaki Kobayashi, Kazuharu Uchida
Publikováno v:
Case Reports in Hematology, Vol 2015 (2015)
Virus-associated hemophagocytic syndrome (HPS) is a potentially fatal complication of immunosuppression for transplantation. However, it presents with heterogeneous clinical symptoms (fever, disturbed consciousness, and hepatosplenomegaly) and labora
Externí odkaz:
https://doaj.org/article/7b9279b85c704961bb2675f0a48488ff
Autor:
Akio, KATAYAMA
Publikováno v:
吉備国際大学研究紀要(人文・社会科学系) = Journal of KIBI International University Humanities and Social Sciences. 29:103-108
Autor:
Makoto Tsujita, Morikuni Nishihira, Norihiko Goto, Yoshihiko Watarai, Akio Katayama, Kunio Morozumi, Kazuharu Uchida, Kandai Nozu, Akira Shimizu, Keiji Horike, Asami Takeda
Publikováno v:
Nephrology. 23:17-21
Apolipoprotein A-I amyloidosis is a rare, autosomal dominant disorder of APOA-1 gene characterized by the deposition of apolipoprotein A-I in various organs and can be classified into either hereditary or nonhereditary form in the absence of a family
Autor:
Shunji Narumi, Akio Katayama, Kazuharu Uchida, Takaaki Kobayashi, Makoto Tsujita, Takayuki Yamamoto, Takahisa Hiramitsu, Asami Takeda, Kunio Morozumi, Norihiko Goto, Yoshihiko Watarai
Publikováno v:
Transplantation. 100:2194-2202
It is unclear whether all donor-specific antibodies (DSA) can cause chronic antibody-mediated rejection (AMR). Subclinical stage before manifestation of renal dysfunction may be a critical period for reversing AMR. The aim of our study was to identif
Autor:
Shinji Narumi, Kenta Iwasaki, Takaaki Kobayashi, Yoshihiko Watarai, Kenta Murotani, Takahisa Hiramitsu, Takayuki Yamamoto, Akio Katayama, Yuko Miwa, Kazuharu Uchida, Yukiko Inanaga
Publikováno v:
Biomarkers. 22:45-54
De novo donor-specific HLA antibody (DSA) would not necessarily contribute to chronic antibody-mediated rejection (CAMR) in kidney transplantation. Here, we investigated whether PBMC miRNAs could be predictable biomarkers for CAMR. Microarray profili
Autor:
Yoshihiko Watarai, Makoto Tsujita, Manabu Okada, Takaaki Kobayashi, Takahisa Hiramitsu, Akio Katayama, Norihiko Goto, Kazuharu Uchida, Shunji Narumi, Takayuki Yamamoto
Publikováno v:
Clinical Journal of the American Society of Nephrology. 11:497-504
Evidence regarding the differences in clinical outcomes after preemptive kidney transplantation (PKT) and non-PKT in Japan is lacking.We conducted a retrospective cohort study at a single center in Japan. Consecutive patients ages18 years old who had
Autor:
Keiji, Horike, Asami, Takeda, Makoto, Tsujita, Norihiko, Goto, Yoshihiko, Watarai, Kazuharu, Uchida, Akio, Katayama, Morikuni, Nishihira, Akira, Shimizu, Kandai, Nozu, Kunio, Morozumi
Publikováno v:
Nephrology (Carlton, Vic.). 23
Apolipoprotein A-I amyloidosis is a rare, autosomal dominant disorder of APOA-1 gene characterized by the deposition of apolipoprotein A-I in various organs and can be classified into either hereditary or nonhereditary form in the absence of a family
Autor:
Koji, Nanmoku, Yoshihiko, Watarai, Shunji, Narumi, Norihiko, Goto, Takayuki, Yamamoto, Makoto, Tsujita, Takahisa, Hiramitsu, Akio, Katayama, Takaaki, Kobayashi, Kazuharu, Uchida
Publikováno v:
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 15(6)
Atherosclerosis is becoming a more common problem for dialysis patients. Therefore, transplant surgeons are faced with the need to develop surgical techniques and procedures for severe atherosclerosis. This study aimed to clarify the clinical feature
Autor:
Takafumi Kuzuya, Yoshihiko Watarai, Akio Katayama, Takaaki Kobayashi, Kazuharu Uchida, Yuko Miwa, Kiyofumi Yamada, Kenta Iwasaki, Masataka Haneda, Katsuo Amioka, Yoko Kurata
Publikováno v:
International Immunopharmacology. 22:384-391
Although therapeutic drug monitoring based on blood concentration has been widely implemented in transplant recipients treated with immunosuppressive agents, clinical adverse events such as rejection, infection or drug-induced toxicity caused by inap